Equipped with advanced cognitive computing technologies, we are able to aggregate and mine disparate types of biomedical datasets to reveal novel contextual vulnerabilities in cancer, and collaborate with leading universities to exploit those vulnerabilities with cutting-edge agents.
We then invest in the most promising experimental agents to demonstrate their therapeutic potential. Finally, we partner with pharmaceutical companies to transform innovative new agents into the breakthrough cancer therapies.
Our approach to cancer research is revolutionary. Applying the exponential power of our cognitive computing platform and a unique multi-scalar systems modeling approach, our team of scientists are able to extract much deeper insights into the molecular contexts that represent the best therapeutic vulnerabilities in cancer. Modeling multi-dimensional disease mechanisms is critical to our ability to discover truly novel therapeutic opportunities. Understanding these mechanisms also allows us to resolve clinical heterogeneity in drug development. Taken together, this unique process empowers us to discover and develop the next generation of cancer therapies with unprecedented speed and precision.
In silico discovery research
Use in silico insights to predict and prioritize
In-licensing of top candidates
Invest in studies to demonstrate safety, efficacy & mechanism
Out-licensing of products
We welcome opportunities to collaborate with leading pharmaceutical companies to advance innovative multi-targeting therapies.
